selehold 45 mg rácsepegteto oldat 2,6 7,5 kg-os macskák számára a.u.v.
krka d.d. novo mesto - szelamektin - rácsepegteto oldat - selamectin - macska
selehold 60 mg rácsepegteto oldat 5,1- 10,0 kg-os kutyák számára a.u.v.
krka d.d. novo mesto - szelamektin - rácsepegteto oldat - selamectin - kutya
selehold 60 mg rácsepegteto oldat 7,6-10,0 kg-os macskák számára a.u.v.
krka d.d. novo mesto - szelamektin - rácsepegteto oldat - selamectin - macska
rinvoq
abbvie deutschland gmbh & co. kg - upadacitinib - arthritis, rheumatoid - immunszuppresszánsok - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
duoflect rácsepegtetõ oldat kutyáknak (10 - 20 kg) a.u.v.
ceva-phylaxia oltóanyagtermelõ zrt. - fipronil, metoprén (s) - rácsepegtetõ oldat - fipronil, kombinációk - kutya
duoflect rácsepegtetõ oldat kutyáknak (2 - 10 kg) és macskáknak (>5 kg) a.u.v.
ceva-phylaxia oltóanyagtermelõ zrt. - fipronil, metoprén (s) - rácsepegtetõ oldat - fipronil, kombinációk - kutya, macska
duoflect rácsepegtetõ oldat kutyáknak (20 - 40 kg) a.u.v.
ceva-phylaxia oltóanyagtermelõ zrt. - fipronil, metoprén (s) - rácsepegtetõ oldat - fipronil, kombinációk - kutya
duoflect rácsepegtetõ oldat kutyáknak (40 - 60 kg) a.u.v.
ceva-phylaxia oltóanyagtermelõ zrt. - fipronil, metoprén (s) - rácsepegtetõ oldat - fipronil, kombinációk - kutya
duoflect rácsepegtetõ oldat macskáknak (0,5 - 5 kg) a.u.v.
ceva-phylaxia oltóanyagtermelõ zrt. - fipronil, metoprén (s) - rácsepegtetõ oldat - fipronil, kombinációk - macska
tsefalen 50 mg/ml por belsoleges szuszpenzióhoz macskák és legfeljebb 20 kg testtömegu kutyák számára a.u.v.
icf industria chimica fine s.r.l. - cefalexin - por belsoleges szuszpenzióhoz - cefalexin - kutya, macska